Nicolas Duployez

Lille, France

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 152 publications

Ruxolitinib for life-threatening corticosteroid-refractory hypereosinophilic syndrome: A multicenter case series.

Ruxolitinib for life-threatening corticosteroid-refractory hypereosinophilic syndrome: A multicenter case series.

Journal: Clinical immunology (Orlando, Fla.)
Published: May 11, 2026

Real-world patterns of treatment intensity and prognostic model performance in older acute myeloid leukemia: insights from the French ALFA-PPP Cohort.

Real-world patterns of treatment intensity and prognostic model performance in older acute myeloid leukemia: insights from the French ALFA-PPP Cohort.

Journal: Leukemia
Published: April 14, 2026

TNFRSF17 genomic profiling guides retreatment with alternative BCMA-directed immunotherapies in multiple myeloma.

TNFRSF17 genomic profiling guides retreatment with alternative BCMA-directed immunotherapies in multiple myeloma.

Journal: Blood advances
Published: March 24, 2026

TNFRSF17 genomic profiling guides retreatment with alternative BCMA-directed immunotherapies in multiple myeloma.

TNFRSF17 genomic profiling guides retreatment with alternative BCMA-directed immunotherapies in multiple myeloma.

Journal: Blood advances
Published: March 24, 2026

Ultra-high-sensitivity next-generation sequencing-based MRD predicts outcome in intensively treated older patients with acute myeloid leukemia: results from the ALFA-1200 cohort.

Ultra-high-sensitivity next-generation sequencing-based MRD predicts outcome in intensively treated older patients with acute myeloid leukemia: results from the ALFA-1200 cohort.

Journal: Blood cancer journal
Published: March 11, 2026

Prognostic impact of intensive chemotherapy in patients with TP53-mutated AML.

Prognostic impact of intensive chemotherapy in patients with TP53-mutated AML.

Journal: Blood cancer journal
Published: March 10, 2026

Clonal and genomic determinants of e1a2 BCR::ABL1 chronic myeloid leukemia: A Fi-LMC study.

Clonal and genomic determinants of e1a2 BCR::ABL1 chronic myeloid leukemia: A Fi-LMC study.

Journal: HemaSphere
Published: February 26, 2026

ELN-DAVID recommendations for NGS-based FLT3-ITD MRD testing for patients with acute myeloid leukemia.

ELN-DAVID recommendations for NGS-based FLT3-ITD MRD testing for patients with acute myeloid leukemia.

Journal: Blood
Published: February 04, 2026

ELN-DAVID Recommendations for NGS-based FLT3-ITD MRD Testing in Patients with Acute Myeloid Leukemia.

ELN-DAVID Recommendations for NGS-based FLT3-ITD MRD Testing in Patients with Acute Myeloid Leukemia.

Journal: Blood
Published: February 04, 2026

CEBP and ZEB2 alterations define three distinct subtypes of B-cell acute lymphoblastic leukemia.

CEBP and ZEB2 alterations define three distinct subtypes of B-cell acute lymphoblastic leukemia.

Journal: HemaSphere
Published: February 01, 2026

Prognostic impact of FLT3-ITD microclones in young adults with acute myeloid leukemia treated with intensive chemotherapy.

Prognostic impact of FLT3-ITD microclones in young adults with acute myeloid leukemia treated with intensive chemotherapy.

Journal: Blood
Published: January 20, 2026

Prognostic impact of FLT3-ITD microclones in young adults with acute myeloid leukemia treated with intensive chemotherapy.

Prognostic impact of FLT3-ITD microclones in young adults with acute myeloid leukemia treated with intensive chemotherapy.

Journal: Blood
Published: January 20, 2026
Showing 1-12 of 152

Last Updated: 09/26/2026